Telix Pharmaceuticals Limited · 2 hours ago
Director, Upstream Product Marketing – Late Stage PSMA
United States
Full-time
Remote
Director/Executive
10+ years expTelix Pharmaceuticals is a dynamic, fast-growing radiopharmaceutical company focused on precision medicine. The Director of Upstream Product Marketing is responsible for shaping the commercial vision and lifecycle strategy for the late-stage PSMA imaging portfolio, ensuring optimal product positioning and driving high-impact commercial strategies.
Biotechnology
Responsibilities
Lead the development, refinement, and execution of commercial and lifecycle strategies for Illuccix®, Gozellix®, and latestage PSMA programs
Serve as the primary commercial thought leader guiding market evolution, competitive positioning, and long-range franchise strategy
Build and steward a deep understanding of customer segments—including imaging centers, urology networks, and integrated specialty groups—to shape portfolio and pipeline decisions
Partner with regional leaders and medical counterparts to proactively identify evidence needs and influence data-generation priorities
Own the development and executive-level delivery of business cases, TAM/SAM analyses, value assessments, and lifecycle scenario modeling
Collaborate with Commercial Strategy & Operations to pressure-test, align, and update late-stage forecasts and financial assumptions
Anticipate market trends, competitive shifts, and adoption patterns to inform PMC submissions and investment decisions
Convert complex commercial analyses into clear, strategic recommendations for regional leadership teams
Act as the senior commercial partner to GDLs, ensuring late-stage development aligns with market needs, differentiation strategy, and launch readiness
Lead cross-functional governance with Medical Affairs, Regulatory, Market Access, and Marketing Operations to ensure regional alignment across lifecycle activities
Oversee commercial contributions to Launch Readiness Reviews (LRRs) and drive post-launch optimization frameworks
Ensure a seamless upstream-to-downstream transition by aligning GTM strategy, messaging, and operational scaling across regions
Oversee the synthesis of competitive intelligence, including clinical progress, regulatory events, launch timing, messaging, and technology advances
Provide strategic insights that shape brand positioning, lifecycle prioritization, and risk mitigation plans
Monitor policy, reimbursement, and market access shifts to anticipate barriers and opportunities for PSMA imaging adoption
Lead high-impact strategic initiatives such as lifecycle indication launches, expansion projects, and multi-regional alignment activities
Drive execution excellence by setting timelines, governance structures, and communication standards for cross-functional teams
Present strategic updates, insights, and recommendations to executive leadership and participate in PMC and portfolio governance forums
Qualification
Required
Bachelor's degree in Marketing, Business, or Life Sciences
10+ years of experience in pharmaceutical, biotech, molecular imaging, or diagnostics marketing, ideally in oncology or urology
Proven experience leading upstream product strategy, lifecycle management, or commercial planning for late-stage assets
Strong ability to synthesize scientific, clinical, and commercial insights into strategic decision-making
Demonstrated success influencing cross-functional teams in complex, matrixed environments
Strong financial and analytical acumen, with experience developing sophisticated forecasts and investment cases
Exceptional communication, executive presentation, and stakeholder leadership skills
Advanced project leadership and organizational capabilities
Preferred
MBA or advanced degree strongly preferred
Benefits
Competitive salaries
Annual performance-based bonuses
An equity-based incentive program
Generous vacation
Paid wellness days
Support for learning and development
Company
Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$493.27MKey Investors
Australian Government
2024-07-23Post Ipo Debt· $429.77M
2022-04-04Grant· $23M
2020-03-16Grant· $0.5M
Leadership Team
Christian Behrenbruch
Group CEO and Managing Director
Kevin Richardson
CEO Americas
Recent News
Benzinga.com
2026-01-22
legacy.thefly.com
2026-01-21
BioWorld Financial Watch
2026-01-21
Company data provided by crunchbase